| 2.44 0 (0%) | 04-19 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 3.98 | 1-year : | 5.82 |
| Resists | First : | 3.4 | Second : | 4.98 |
| Pivot price | 2.84  |
|||
| Supports | First : | 0.85 | Second : | 0.7 |
| MAs | MA(5) : | 2.52 |
MA(20) : | 2.83  |
| MA(100) : | 1.34 |
MA(250) : | 1.14 |
|
| MACD | MACD : | 0.2 |
Signal : | 0.3 |
| %K %D | K(14,3) : | 4.6 |
D(3) : | 6.4 |
| RSI | RSI(14): 51.2 | |||
| 52-week | High : | 4.98 | Low : | 0.75 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ XTLB ] has closed above bottom band by 16.4%. Bollinger Bands are 87.3% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 23 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 2.48 - 2.5 | 2.5 - 2.51 |
| Low: | 2.38 - 2.4 | 2.4 - 2.42 |
| Close: | 2.41 - 2.44 | 2.44 - 2.46 |
XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases. The company's lead drug candidate is hCDR1, a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. It has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was incorporated in 1993 and is headquartered in Ramat Gan, Israel.
Thu, 21 Mar 2024
XTL Biopharmaceuticals Convenes Extraordinary General Meeting - TipRanks.com - TipRanks
Wed, 20 Mar 2024
XTL Biopharmaceuticals Acquires The Social Proxy - TipRanks.com - TipRanks
Wed, 20 Mar 2024
US Stocks Edge Lower Ahead Of Fed's Decision; General Mills Earnings Top Views - Markets Insider
Wed, 20 Mar 2024
XTL Biopharmaceuticals acquires Social Proxy for AI expansion - Investing.com
Wed, 20 Mar 2024
Is X T L Biopharmaceuticals Ltd (XTLB) Stock a Bad Value Wednesday? - InvestorsObserver
Mon, 18 Mar 2024
X T L Biopharmaceuticals Ltd (XTLB) Stock Has Gained 9.78% This Week: Buy, Hold, or Sell? - InvestorsObserver
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 5 (M) |
| Shares Float | 413 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 4.5 (%) |
| Shares Short | 437 (K) |
| Shares Short P.Month | 2 (K) |
| EPS | -0.41 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -13.1 % |
| Return on Equity (ttm) | -62 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.15 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | -6.1 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|